Autologous arteriovenous fistula dysfunction in hemodialysis patients
Conditions
Interventions
Experimental group(main study):Near infrared irradiates arteriovenous fistula for 30 minutes 3 times a week
Control group( main study):Usual care for 30 minutes three times a week for 12 months.
Experimental group(sub study):Near infrared irradiates arteriovenous fistula for 30 minutes.
Control group(sub study):Usual care for 30 minutes.
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; 2. The use of autogenous arteriovenous fistula was >1 month; 3. The dialysis time was more than 3 months, and no intervention was performed for AVF in nearly 1 month.
Exclusion criteria
Exclusion criteria: 1. Patients treated with NIR/FIR 1 month before enrollment; 2. Patients treated with central venous catheter and AVF; 3. Combined peritoneal and hemodialysis treatment; 4. live donor kidney transplantation is planned; 5. Life expectancy ( < 1 year); 6. Patients with hemodialysis less than 3 times per week; 7. Patients with contraindications to photoheat therapy, such as bleeding tendency, high fever, active tuberculosis, acute suppurative inflammation, photoallergy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary fistula patency rate within 12 months;albumin;BA blood flow volume;BA diameter;BA blood flow velocity;BA resistance index;venous diameter at anastomosis site; | — |
Secondary
| Measure | Time frame |
|---|---|
| Brachial artery diameter;BA blood flow volume;BA blood flow velocity;BA resistance index;anastomosis site diameter;artery diameter at anastomosis site;venous diameter at anastomosis site;white cell;blood urea nitrogen;blood platelet;serum creatinine ;free parathyroid hormone;haemoglobin (HB);calcium;serum potassium;phosphate;hypersensitive C-reactive protein;25-OH D3;lipid profile;inspection(stealing syndrome, pseudoaneurysm, infection, and so on);palpation;auscultation;arm lift test;pulse enhancement test;muscle spasm; AVFhematoma;puncture failure;puncture pain;blood pressure;Skin temperature at the site of exposure;venous pressure;artery pressure;heart rate;Soluble intercellular adhesion molecule (sICAM);soluble intervascular adhesion molecules (sVCAM);sE-selectin;IL-1ß;IL-6;IL-8;IL-10;tumour necrosis factor alpha(TNF-a);monocyte chemoattractant protein 1;Vascular endothelial growth factor (VEGF);Heme-Oxygenase 1;asymmetric dimethylarginine (ADMA);Nitrite;Arteriovenous fistula secondary patency rate;Assisted primary patency rate; | — |
Countries
China
Contacts
Public ContactChunyan Su
Peking University Third Hospital
Outcome results
None listed